182 related articles for article (PubMed ID: 25016799)
41. Mutations in TET2 and DNMT3A genes are associated with changes in global and gene-specific methylation in acute myeloid leukemia.
Ponciano-Gómez A; Martínez-Tovar A; Vela-Ojeda J; Olarte-Carrillo I; Centeno-Cruz F; Garrido E
Tumour Biol; 2017 Oct; 39(10):1010428317732181. PubMed ID: 28992762
[TBL] [Abstract][Full Text] [Related]
42. Epigenetic Changes in Neoplastic Mast Cells and Potential Impact in Mastocytosis.
Reszka E; Jabłońska E; Wieczorek E; Valent P; Arock M; Nilsson G; Nedoszytko B; Niedoszytko M
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33803981
[TBL] [Abstract][Full Text] [Related]
43. Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma.
Fukumoto K; Nguyen TB; Chiba S; Sakata-Yanagimoto M
Cancer Sci; 2018 Mar; 109(3):490-496. PubMed ID: 28889481
[TBL] [Abstract][Full Text] [Related]
44. Clinical implications of novel mutations in epigenetic modifiers in AML.
Abdel-Wahab O; Patel J; Levine RL
Hematol Oncol Clin North Am; 2011 Dec; 25(6):1119-33. PubMed ID: 22093580
[TBL] [Abstract][Full Text] [Related]
45. Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia.
Roche-Lestienne C; Marceau A; Labis E; Nibourel O; Coiteux V; Guilhot J; Legros L; Nicolini F; Rousselot P; Gardembas M; Helevaut N; Frimat C; Mahon FX; Guilhot F; Preudhomme C;
Leukemia; 2011 Oct; 25(10):1661-4. PubMed ID: 21637286
[No Abstract] [Full Text] [Related]
46. Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Wang F; Morita K; DiNardo CD; Furudate K; Tanaka T; Yan Y; Patel KP; MacBeth KJ; Wu B; Liu G; Frattini M; Matthews JA; Little LD; Gumbs C; Song X; Zhang J; Thompson EJ; Kadia TM; Garcia-Manero G; Jabbour E; Ravandi F; Bhalla KN; Konopleva M; Kantarjian HM; Andrew Futreal P; Takahashi K
Nat Commun; 2021 May; 12(1):2607. PubMed ID: 33972549
[TBL] [Abstract][Full Text] [Related]
47. [Clonal haematopoiesis: A concise review].
Danlos FX; Papo M; Micol JB
Rev Med Interne; 2019 Oct; 40(10):684-692. PubMed ID: 31126662
[TBL] [Abstract][Full Text] [Related]
48. EZH2, new diagnosis and prognosis marker in acute myeloid leukemia patients.
Mechaal A; Menif S; Abbes S; Safra I
Adv Med Sci; 2019 Sep; 64(2):395-401. PubMed ID: 31331874
[TBL] [Abstract][Full Text] [Related]
49. Mutations in epigenetic modifiers in acute myeloid leukemia and their clinical utility.
Hou HA; Tien HF
Expert Rev Hematol; 2016 May; 9(5):447-69. PubMed ID: 26789100
[TBL] [Abstract][Full Text] [Related]
50. Epigenetic Identity in AML Depends on Disruption of Nonpromoter Regulatory Elements and Is Affected by Antagonistic Effects of Mutations in Epigenetic Modifiers.
Glass JL; Hassane D; Wouters BJ; Kunimoto H; Avellino R; Garrett-Bakelman FE; Guryanova OA; Bowman R; Redlich S; Intlekofer AM; Meydan C; Qin T; Fall M; Alonso A; Guzman ML; Valk PJM; Thompson CB; Levine R; Elemento O; Delwel R; Melnick A; Figueroa ME
Cancer Discov; 2017 Aug; 7(8):868-883. PubMed ID: 28408400
[TBL] [Abstract][Full Text] [Related]
51. Recent Clinical Update of Acute Myeloid Leukemia: Focus on Epigenetic Therapies.
Lee E; Koh Y; Hong J; Eom HS; Yoon SS
J Korean Med Sci; 2021 Apr; 36(13):e85. PubMed ID: 33821592
[TBL] [Abstract][Full Text] [Related]
52. Comparative examination of various PCR-based methods for DNMT3A and IDH1/2 mutations identification in acute myeloid leukemia.
Berenstein R; Blau IW; Kar A; Cay R; Sindram A; Seide C; Blau O
J Exp Clin Cancer Res; 2014 May; 33(1):44. PubMed ID: 24887327
[TBL] [Abstract][Full Text] [Related]
53. Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-targeted therapy.
Fathi AT; Abdel-Wahab O
Adv Hematol; 2012; 2012():469592. PubMed ID: 21811504
[TBL] [Abstract][Full Text] [Related]
54. Molecular subtypes of NPM1 mutations have different clinical profiles, specific patterns of accompanying molecular mutations and varying outcomes in intermediate risk acute myeloid leukemia.
Alpermann T; Schnittger S; Eder C; Dicker F; Meggendorfer M; Kern W; Schmid C; Aul C; Staib P; Wendtner CM; Schmitz N; Haferlach C; Haferlach T
Haematologica; 2016 Feb; 101(2):e55-8. PubMed ID: 26471486
[No Abstract] [Full Text] [Related]
55. Epigenetic modifiers in normal and malignant hematopoiesis.
Haladyna JN; Yamauchi T; Neff T; Bernt KM
Epigenomics; 2015; 7(2):301-20. PubMed ID: 25942537
[TBL] [Abstract][Full Text] [Related]
56. DNMT3A mutations mediate the epigenetic reactivation of the leukemogenic factor MEIS1 in acute myeloid leukemia.
Ferreira HJ; Heyn H; Vizoso M; Moutinho C; Vidal E; Gomez A; Martínez-Cardús A; Simó-Riudalbas L; Moran S; Jost E; Esteller M
Oncogene; 2016 Jun; 35(23):3079-82. PubMed ID: 26434589
[TBL] [Abstract][Full Text] [Related]
57. Somatic RHOA mutation in angioimmunoblastic T cell lymphoma.
Sakata-Yanagimoto M; Enami T; Yoshida K; Shiraishi Y; Ishii R; Miyake Y; Muto H; Tsuyama N; Sato-Otsubo A; Okuno Y; Sakata S; Kamada Y; Nakamoto-Matsubara R; Tran NB; Izutsu K; Sato Y; Ohta Y; Furuta J; Shimizu S; Komeno T; Sato Y; Ito T; Noguchi M; Noguchi E; Sanada M; Chiba K; Tanaka H; Suzukawa K; Nanmoku T; Hasegawa Y; Nureki O; Miyano S; Nakamura N; Takeuchi K; Ogawa S; Chiba S
Nat Genet; 2014 Feb; 46(2):171-5. PubMed ID: 24413737
[TBL] [Abstract][Full Text] [Related]
58. DNMT3A mutations in acute myeloid leukemia.
Shah MY; Licht JD
Nat Genet; 2011 Mar; 43(4):289-90. PubMed ID: 21445072
[TBL] [Abstract][Full Text] [Related]
59. Detection of high-frequency and novel DNMT3A mutations in acute myeloid leukemia by high-resolution melting curve analysis.
Singh RR; Bains A; Patel KP; Rahimi H; Barkoh BA; Paladugu A; Bisrat T; Ravandi-Kashani F; Cortes JE; Kantarjian HM; Medeiros LJ; Luthra R
J Mol Diagn; 2012 Jul; 14(4):336-45. PubMed ID: 22642896
[TBL] [Abstract][Full Text] [Related]
60. A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients.
Drusbosky LM; Singh NK; Hawkins KE; Salan C; Turcotte M; Wise EA; Meacham A; Vijay V; Anderson GG; Kim CC; Radhakrishnan S; Ullal Y; Talawdekar A; Sikora H; Nair P; Khanna-Gupta A; Abbasi T; Vali S; Guha S; Farhadfar N; Murthy HS; Horn BN; Leather HL; Castillo P; Tucker C; Cline C; Pettiford L; Lamba JK; Moreb JS; Brown RA; Norkin M; Hiemenz JW; Hsu JW; Slayton WB; Wingard JR; Cogle CR
Blood Adv; 2019 Jun; 3(12):1837-1847. PubMed ID: 31208955
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
